Cargando…

Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection

The development of sodium-glucose transporter 2 inhibitor (SGLT2i) broadens the therapeutic strategies in treating diabetes mellitus. By inhibiting sodium and glucose reabsorption from the proximal tubules, the improvement in insulin resistance and natriuresis improved the cardiovascular mortality i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hou, Yi-Chou, Zheng, Cai-Mei, Yen, Tzung-Hai, Lu, Kuo-Cheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7660105/ https://www.ncbi.nlm.nih.gov/pubmed/33105763 http://dx.doi.org/10.3390/ijms21217833

Ejemplares similares

An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
por: Salvatore, Teresa, et al.
Publicado: (2022)

Cardiorenal protection of SGLT2 inhibitors—Perspectives from metabolic reprogramming
por: Gao, Yue-Ming, et al.
Publicado: (2022)

SGLT2 Inhibitor–Induced Sympathoinhibition: A Novel Mechanism for Cardiorenal Protection
por: Herat, Lakshini Y., et al.
Publicado: (2020)

Mechanisms of Cardiorenal Protection With SGLT2 Inhibitors in Patients With T2DM Based on Network Pharmacology
por: Wang, Anzhu, et al.
Publicado: (2022)

The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection
por: Brown, Emily, et al.
Publicado: (2021)

Class effects of SGLT2 inhibitors on cardiorenal outcomes
por: Kluger, Aaron Y., et al.
Publicado: (2019)

Meta-Analysis on the Safety and Cardiorenal Efficacy of SGLT2 Inhibitors in Patients Without T2DM
por: Li, Lu-Feng, et al.
Publicado: (2021)

The Na/K-ATPase Signaling and SGLT2 Inhibitor-Mediated Cardiorenal Protection: A Crossed Road?
por: Liu, Jiang, et al.
Publicado: (2021)

Are the Cardiorenal Benefits of SGLT2 Inhibitors Due to Inhibition of the Sympathetic Nervous System?
por: Verma, Subodh
Publicado: (2020)

Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease
por: Georgianos, Panagiotis I., et al.
Publicado: (2022)

Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection
por: Sridhar, Vikas S., et al.
Publicado: (2020)

SGLT2 inhibitors in the treatment of type 2 cardiorenal syndrome: Focus on renal tubules
por: Wang, Yajiao, et al.
Publicado: (2023)

A Systematic Review of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Sympathetic Nervous System Inhibition: An Underrated Mechanism of Cardiorenal Protection
por: Raza, Shafaat, et al.
Publicado: (2022)

SGLT2 Inhibitors and the Cardiorenal Continuum: A Paradigm Shift in the Treatment of Patients with T2D
por: Escalada, Javier
Publicado: (2022)

Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis
por: Packer, Milton
Publicado: (2022)

Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors: Delving Into the Potential Benefits of Cardiorenal Protection Beyond the Treatment of Type-2 Diabetes Mellitus
por: Srinivas, Natasha, et al.
Publicado: (2021)

Organophosphate pesticides and new-onset diabetes mellitus: From molecular mechanisms to a possible therapeutic perspective
por: Chung, Ya-Ling, et al.
Publicado: (2021)

Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk
por: Goncalves, Edison, et al.
Publicado: (2018)

Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors
por: Prandi, Francesca Romana, et al.
Publicado: (2022)

Sodium-glucose Co-transporter-2 inhibitors (SGLT2I): A class of drugs with promising cardiorenal protective effects beyond glycemic control
por: Zaawari, Abdullah, et al.
Publicado: (2022)

SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs
por: Giugliano, Dario, et al.
Publicado: (2021)

Network Meta-Analysis on the Effects of SGLT2 Inhibitors Versus Finerenone on Cardiorenal Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease
por: Zhao, Li-Min, et al.
Publicado: (2022)

Effects of SGLT2 inhibitors on haematocrit and haemoglobin levels and the associated cardiorenal benefits in T2DM patients: A meta‐analysis
por: Tian, Qi, et al.
Publicado: (2021)

Role of Vitamin D in Uremic Vascular Calcification
por: Hou, Yi-Chou, et al.
Publicado: (2017)

Does Combination Therapy With SGLT2 Inhibitors and Renin–Angiotensin System Blockers Lead to Greater Reduction in Cardiorenal Events Among Patients With Type 2 Diabetes?
por: Zhao, Li-Min, et al.
Publicado: (2021)

Enhanced Cardiorenal Protective Effects of Combining SGLT2 Inhibition, Endothelin Receptor Antagonism and RAS Blockade in Type 2 Diabetic Mice
por: Vergara, Ander, et al.
Publicado: (2022)

The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs
por: Giugliano, Dario, et al.
Publicado: (2022)

Underprescription of SGLT2i and GLP-1 RA: CAREPRO-T2D (Cardiorenal Protection in Type 2 Diabetes) Cross-Sectional Study
por: Simões de Carvalho, Francisco, et al.
Publicado: (2023)

The molecular mechanisms and intervention strategies of mitophagy in cardiorenal syndrome
por: Yao, Mengying, et al.
Publicado: (2022)

Digging deep into cells to find mechanisms of kidney protection by SGLT2 inhibitors
por: Tuttle, Katherine R.
Publicado: (2023)

Abnormal apelin-ACE2 and SGLT2 signaling contribute to adverse cardiorenal injury in patients with COVID-19
por: Li, Xue-Ting, et al.
Publicado: (2021)

Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors
por: Qiu, Mei, et al.
Publicado: (2021)

Cardiorenal protective effect of sodium–glucose cotransporter 2 inhibitors and mitochondrial function
por: Lee, Hong Kyu
Publicado: (2019)

Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study
por: Lugner, Moa, et al.
Publicado: (2021)

Possible renoprotective mechanisms of SGLT2 inhibitors
por: Nishiyama, Akira, et al.
Publicado: (2023)

Cardiorenal Protection in Diabetic Kidney Disease
por: Lee, Jason F., et al.
Publicado: (2021)

Structural mechanism of SGLT1 inhibitors
por: Niu, Yange, et al.
Publicado: (2022)

Repurposing SGLT-2 Inhibitors to Target Aging: Available Evidence and Molecular Mechanisms
por: La Grotta, Rosalba, et al.
Publicado: (2022)

Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
por: Schernthaner, Guntram, et al.
Publicado: (2020)

Electrocardiographic changes associated with SGLT2 inhibitors and non-SGLT2 inhibitors: A multi-center retrospective study
por: Wu, Victor Chien-Chia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_52mpparlm9nup9id8ijdaq0aac